Previous studies associated with RRM1 expression in NSCLC patients largely demonstrated that low or negative RRM1 levels in patients with advanced NSCLC receiving gemcitabine-based regimens were correlated with higher response rates and a better prognosis [18]. This evidence concerns the gene RRM1 and non-small cell lung carcinoma.